Table of Contents

    Topic review

    PKLR Gene

    Subjects: Genetics
    View times: 5
    Submitted by: Lily Guo
    (This entry belongs to Entry Collection "MedlinePlus ")


    pyruvate kinase L/R

    1. Introduction

    The PKLR gene is active (expressed) in the liver and in red blood cells, where it provides instructions for producing an enzyme called pyruvate kinase. This enzyme is involved in a critical energy-producing process known as glycolysis. During glycolysis, the simple sugar glucose is broken down to produce energy. Specifically, pyruvate kinase is involved in the last step of the glycolytic pathway. In this step, a cluster of oxygen and phosphorus atoms (a phosphate group) is moved from a molecule called phosphoenolpyruvate to another molecule called adenosine diphosphate (ADP), resulting in molecules called pyruvate and adenosine triphosphate (ATP). ATP is the cell's main energy source.

    2. Health Conditions Related to Genetic Changes

    2.1. Pyruvate kinase deficiency

    More than 200 mutations in the PKLR gene have been identified in people with pyruvate kinase deficiency. People with this disorder have two PKLR gene mutations in each cell. Most of the mutations that cause pyruvate kinase deficiency replace single protein building blocks (amino acids) in the pyruvate kinase enzyme or result in an enzyme that is abnormally short. The mutations lead to reduced pyruvate kinase enzyme function, causing a shortage of ATP in red blood cells and increased levels of other molecules produced earlier in the glycolysis process. The abnormal red blood cells are gathered up by the spleen and destroyed.

    The resulting shortage of oxygen-carrying red blood cells (anemia) leads to extreme tiredness (fatigue), unusually pale skin (pallor), and shortness of breath. Iron and a molecule called bilirubin are released when red blood cells are destroyed, resulting in an excess of these substances circulating in the blood. Excess bilirubin in the blood causes yellowing of the eyes and skin (jaundice) and increases the risk of developing small pebble-like deposits in the gallbladder or bile ducts (gallstones).

    2.2. Other disorders

    Researchers believe that people who have one copy of a PKLR gene mutation in each cell may be partially protected against malaria, an infectious disease carried by a certain type of mosquito. Mutations that lead to a reduction in the amount of functional pyruvate kinase appear to make it more difficult for this parasite to invade red blood cells. Studies indicate that individuals from populations in Africa, where malaria is a frequent cause of death in children, carry one copy of a mutated PKLR gene in each cell more than twice as often as individuals of European descent. The increased frequency of PKLR gene mutations may contribute to resistance against malaria in these African populations.

    3. Other Names for This Gene

    • PK1
    • PKL
    • PKR
    • PKRL
    • pyruvate kinase 1
    • pyruvate kinase isozyme R/L
    • pyruvate kinase type L
    • pyruvate kinase, liver and blood cell
    • pyruvate kinase, liver and RBC
    • R-type/L-type pyruvate kinase
    • red cell/liver pyruvate kinase
    • RPK

    The entry is from


    1. Ayi K, Min-Oo G, Serghides L, Crockett M, Kirby-Allen M, Quirt I, Gros P, KainKC. Pyruvate kinase deficiency and malaria. N Engl J Med. 2008 Apr24;358(17):1805-10. doi: 10.1056/NEJMoa072464.
    2. Beutler E, Gelbart T. Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood. 2000 Jun1;95(11):3585-8.
    3. Climent F, Roset F, Repiso A, Pérez de la Ossa P. Red cell glycolytic enzymedisorders caused by mutations: an update. Cardiovasc Hematol Disord Drug Targets.2009 Jun;9(2):95-106. Review.
    4. Durand PM, Coetzer TL. Pyruvate kinase deficiency protects against malaria in humans. Haematologica. 2008 Jun;93(6):939-40. doi: 10.3324/haematol.12450.
    5. Rider NL, Strauss KA, Brown K, Finkenstedt A, Puffenberger EG, Hendrickson CL,Robinson DL, Muenke N, Tselepis C, Saunders L, Zoller H, Morton DH. Erythrocytepyruvate kinase deficiency in an old-order Amish cohort: longitudinal risk anddisease management. Am J Hematol. 2011 Oct;86(10):827-34. doi: 10.1002/ajh.22118.
    6. van Wijk R, Huizinga EG, van Wesel AC, van Oirschot BA, Hadders MA, vanSolinge WW. Fifteen novel mutations in PKLR associated with pyruvate kinase (PK) deficiency: structural implications of amino acid substitutions in PK. Hum Mutat.2009 Mar;30(3):446-53. doi: 10.1002/humu.20915.
    7. van Wijk R, van Solinge WW. The energy-less red blood cell is lost:erythrocyte enzyme abnormalities of glycolysis. Blood. 2005 Dec15;106(13):4034-42.
    8. Zanella A, Fermo E, Bianchi P, Chiarelli LR, Valentini G. Pyruvate kinasedeficiency: the genotype-phenotype association. Blood Rev. 2007 Jul;21(4):217-31.
    9. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinasedeficiency: molecular and clinical aspects. Br J Haematol. 2005 Jul;130(1):11-25.Review.